Annual report pursuant to Section 13 and 15(d)

Summary of significant accounting policies (Tables)

v3.5.0.2
Summary of significant accounting policies (Tables)
12 Months Ended
Jul. 31, 2016
Accounting Policies [Abstract]  
Schedule Of Segment Revenue And Revenue Percentage [Table Text Block] The following table summarizes the Clinical Lab segment’s net revenues and revenue percentages by revenue category:

    Years Ended July 31,
    2016     2015     2014  
Revenue category   Amount     %     Amount     %     Amount     %  
Third-party payers   $ 40,211       57     $ 35,631       56     $   29,509       50  
Patient self-pay     14,744       21       11,028       17       11,204       19  
Medicare     11,392       16       11,981       19       12,815       22  
HMO’s     4,568       6       4,774       8       5,161       9  
Total   $ 70,915       100 %   $ 63,414       100 %   $ 58,689       100 %
Schedule Of Accounts Receivable By Segment [Table Text Block] The following is a table of the Company’s net accounts receivable by segment.

    July 31, 2016     July 31, 2015  
Net accounts receivable by segment   Amount     %     Amount     %  
Clinical Labs (by billing category)                                
Third party payers   $ 6,868       67     $ 3,595       44  
Patient self-pay     1,676       16       3,213       39  
Medicare     1,486       14       1,081       13  
HMO’s     334       3       305       4  
Total Clinical Labs     10,364       100 %     8,194       100 %
                                 
Total Life Sciences     4,228               3,915          
Total accounts receivable – net   $ 14,592             $ 12,109          
Schedule of Allowance for Doubtful Accounts Receivable [Table Text Block] Changes in the Company’s allowance for doubtful accounts are as follows:

    July 31, 2016     July 31, 2015  
Beginning balance   $ 1,786     $ 2,142  
Provision for doubtful accounts     2,336       2,284  
Write-offs     (605 )     (2,640 )
Ending balance   $ 3,517     $ 1,786  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] The following table sets forth the computation of basic and diluted net loss per share for the years ended July 31:

    2016     2015     2014  
Net income (loss)   $ 45,286     $ (2,285 )   $ (9,977 )
                         
Weighted-average common shares outstanding - basic     46,153       45,355       42,561  
Add: effect of dilutive stock options and restricted stock     449              
Weighted-average common shares outstanding - diluted     46,602       45,355       42,561  
                         
Net income (loss) per share – basic   $ 0.98     $ (0.05 )   $ (0.23 )
Net income (loss) per share – diluted   $ 0.97     $ (0.05 )   $ (0.23 )
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statement of operations for the years ended July 31:

    2016     2015     2014  
Cost of clinical laboratory services   $ 6     $ 5     $ 9  
Research and development           2       1  
Selling, general and administrative     519       422       584  
    $ 525     $ 429     $ 594